{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:21:03Z","timestamp":1783002063890,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST110-2320-B-075-003-MY3"],"award-info":[{"award-number":["MOST110-2320-B-075-003-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024990","name":"National Yang Ming Chiao Tung University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An integrative histologic and molecular classification of thyroid tumors has become clinically relevant due to the potential role in risk stratification and selection of targeted therapy. In this review, we discuss the applications of six \u201cnext-generation\u201d immunohistochemical markers, namely BRAF V600E (clone VE1), RAS Q61R (clone SP174), pan-TRK (clone EPR 17341), ALK (clones 5A4 or D5F3), PTEN, and \u03b2-catenin in the pathologic diagnosis and molecular classification of thyroid tumors. These biomarkers allow the in situ examination of tumor tissue and assist in the diagnosis and pathologic staging by highlighting tumor border and patterns of invasion, identifying isolated tumor cells in lymph nodes, distinguishing lymph node metastasis from benign intranodal thyroid inclusions, and diagnosing multicentric thyroid carcinomas with discordant molecular drivers. Furthermore, it can identify specific thyroid neoplasms that may occur sporadically or may be associated with hereditary syndromes. The next-generation immunohistochemistry provides a novel solution to challenging issues in thyroid pathology and fast turn-around time for accurate molecular classification and further guidance of therapeutic management.<\/jats:p>","DOI":"10.1007\/s12022-025-09851-6","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T06:08:22Z","timestamp":1742450902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Next-Generation Immunohistochemistry in Thyroid Neoplasm: A Practical Review on the Applications in Diagnosis and Molecular Classification"],"prefix":"10.1007","volume":"36","author":[{"given":"Jonathan P.","family":"Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-2784","authenticated-orcid":false,"given":"Jen-Fan","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"9851_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"The Cancer Genome Atlas Research Network","year":"2014","unstructured":"The Cancer Genome Atlas Research Network (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159: 676-690.","journal-title":"Cell"},{"key":"9851_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/hed.27025","volume":"44","author":"DC Shonka Jr","year":"2022","unstructured":"Shonka DC, Jr., Ho A, Chintakuntlawar AV et al. (2022) American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head Neck 44: 1277-1300.","journal-title":"Head Neck"},{"key":"9851_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.path.2022.09.007","volume":"16","author":"YH Chu","year":"2023","unstructured":"Chu YH (2023) This is Your Thyroid on Drugs: Targetable Mutations and Fusions in Thyroid Carcinoma. Surg Pathol Clin 16: 57-73.","journal-title":"Surg Pathol Clin"},{"key":"9851_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/his.13373","volume":"72","author":"J Guilmette","year":"2018","unstructured":"Guilmette J, Nose V (2018) Hereditary and familial thyroid tumours. Histopathology 72: 70-81.","journal-title":"Histopathology"},{"key":"9851_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/PAS.0000000000001663","volume":"45","author":"JL Hornick","year":"2021","unstructured":"Hornick JL (2021) Replacing Molecular Genetic Testing With Immunohistochemistry Using Antibodies That Recognize the Protein Products of Gene Rearrangements: \u201cNext-generation\u201d Immunohistochemistry. Am J Surg Pathol 45: 584-586.","journal-title":"Am J Surg Pathol"},{"key":"9851_CR6","doi-asserted-by":"publisher","first-page":"100242","DOI":"10.1016\/j.modpat.2023.100242","volume":"36","author":"JF Hang","year":"2023","unstructured":"Hang JF, Chen JY, Kuo PC et al. (2023) A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases. Mod Pathol 36: 100242.","journal-title":"Mod Pathol"},{"key":"9851_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","volume":"122","author":"D Capper","year":"2011","unstructured":"Capper D, Preusser M, Habel A et al. (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122: 11-19.","journal-title":"Acta Neuropathol"},{"key":"9851_CR8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/j.semdp.2015.02.010","volume":"32","author":"LL Ritterhouse","year":"2015","unstructured":"Ritterhouse LL, Barletta JA (2015) BRAF V600E mutation-specific antibody: A review. Semin Diagn Pathol 32: 400-408.","journal-title":"Semin Diagn Pathol"},{"key":"9851_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/his.12903","volume":"69","author":"JF Hang","year":"2016","unstructured":"Hang JF, Li AF, Chang SC, Liang WY (2016) Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test. Histopathology 69: 54-62.","journal-title":"Histopathology"},{"key":"9851_CR10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s12105-020-01166-8","volume":"14","author":"KG Parker","year":"2020","unstructured":"Parker KG, White MG, Cipriani NA (2020) Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis. Head Neck Pathol 14: 1067-1079.","journal-title":"Head Neck Pathol"},{"key":"9851_CR11","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/modpathol.2010.116","volume":"23","author":"CK Jung","year":"2010","unstructured":"Jung CK, Kang YG, Bae JS, Lim DJ, Choi YJ, Lee KY (2010) Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 23: 1201-1208.","journal-title":"Mod Pathol"},{"key":"9851_CR12","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/modpathol.2015.92","volume":"28","author":"G Tallini","year":"2015","unstructured":"Tallini G, de Biase D, Durante C et al. (2015) BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study. Mod Pathol 28: 1343-1359.","journal-title":"Mod Pathol"},{"key":"9851_CR13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/PAS.0000000000002256","volume":"48","author":"JP Rivera","year":"2024","unstructured":"Rivera JP, Yeh YC, Chen PC, Hang JF (2024) Multifocal Papillary Thyroid Carcinomas With Discordant Molecular Drivers: Emphasizing the Morphology and Collision Tumors. Am J Surg Pathol 48: 1359-1371.","journal-title":"Am J Surg Pathol"},{"key":"9851_CR14","unstructured":"WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. 5th ed. Lyon (France): International Agency for Research on Cancer 2022"},{"key":"9851_CR15","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1210\/jc.2006-1006","volume":"91","author":"Z Zhu","year":"2006","unstructured":"Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE (2006) Prevalence of RET\/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 91: 3603-3610.","journal-title":"J Clin Endocrinol Metab"},{"key":"9851_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1158\/1078-0432.CCR-08-0933","volume":"15","author":"YC Henderson","year":"2009","unstructured":"Henderson YC, Shellenberger TD, Williams MD et al. (2009) High rate of BRAF and RET\/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 15: 485-491.","journal-title":"Clin Cancer Res"},{"key":"9851_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1210\/jc.2011-0618","volume":"97","author":"A Guerra","year":"2012","unstructured":"Guerra A, Sapio MR, Marotta V et al. (2012) The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 97: 517-524.","journal-title":"J Clin Endocrinol Metab"},{"key":"9851_CR18","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1089\/thy.2013.0610","volume":"24","author":"M Zou","year":"2014","unstructured":"Zou M, Baitei EY, Alzahrani AS et al. (2014) Concomitant RAS, RET\/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid 24: 1256-1266.","journal-title":"Thyroid"},{"key":"9851_CR19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1210\/jc.2015-4031","volume":"101","author":"A Finkel","year":"2016","unstructured":"Finkel A, Liba L, Simon E et al. (2016) Subclonality for BRAF Mutation in Papillary Thyroid Carcinoma Is Associated With Earlier Disease Stage. J Clin Endocrinol Metab 101: 1407-1413.","journal-title":"J Clin Endocrinol Metab"},{"key":"9851_CR20","doi-asserted-by":"publisher","first-page":"E1414","DOI":"10.1210\/jc.2013-1408","volume":"98","author":"RA Ghossein","year":"2013","unstructured":"Ghossein RA, Katabi N, Fagin JA (2013) Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metab 98: E1414-1421.","journal-title":"J Clin Endocrinol Metab"},{"key":"9851_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/cncr.28484","volume":"120","author":"RJ Leeman-Neill","year":"2014","unstructured":"Leeman-Neill RJ, Kelly LM, Liu P et al. (2014) ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer 120: 799-807.","journal-title":"Cancer"},{"key":"9851_CR22","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","volume":"381","author":"M Xing","year":"2013","unstructured":"Xing M, Haugen BR, Schlumberger M (2013) Progress in molecular-based management of differentiated thyroid cancer. Lancet 381: 1058-1069.","journal-title":"Lancet"},{"key":"9851_CR23","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/1097-0142(196908)24:2<302::AID-CNCR2820240213>3.0.CO;2-V","volume":"24","author":"JS Meyer","year":"1969","unstructured":"Meyer JS, Steinberg LS (1969) Microscopically benign thyroid follicles in cervical lymph nodes. Serial section study of lymph node inclusions and entire thyroid gland in 5 cases. Cancer 24: 302-311.","journal-title":"Cancer"},{"key":"9851_CR24","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1007\/s00405-015-3786-3","volume":"273","author":"A Triantafyllou","year":"2016","unstructured":"Triantafyllou A, Williams MD, Angelos P et al. (2016) Incidental findings of thyroid tissue in cervical lymph nodes: old controversy not yet resolved? Eur Arch Otorhinolaryngol 273: 2867-2875.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"9851_CR25","doi-asserted-by":"crossref","unstructured":"Chuang YC, Kuo YJ, Hang JF (2024) Intranodal thyroid inclusions revisited: a morphological analysis and application of BRAF VE1 immunohistochemistry. Histopathology [online ahead of print]","DOI":"10.1111\/his.15394"},{"key":"9851_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","volume":"21","author":"AJ Hanrahan","year":"2024","unstructured":"Hanrahan AJ, Chen Z, Rosen N, Solit DB (2024) BRAF - a tumour-agnostic drug target with lineage-specific dependencies. Nat Rev Clin Oncol 21: 224-247.","journal-title":"Nat Rev Clin Oncol"},{"key":"9851_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc3431","volume":"13","author":"M Xing","year":"2013","unstructured":"Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13: 184-199.","journal-title":"Nat Rev Cancer"},{"key":"9851_CR28","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1001\/jamaoncol.2016.0386","volume":"2","author":"YE Nikiforov","year":"2016","unstructured":"Nikiforov YE, Seethala RR, Tallini G et al. (2016) Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol 2: 1023-1029.","journal-title":"JAMA Oncol"},{"key":"9851_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12022-024-09812-5","volume":"35","author":"JC Hernandez-Prera","year":"2024","unstructured":"Hernandez-Prera JC, Wenig BM (2024) RAS-Mutant Follicular Thyroid Tumors: A Continuous Challenge for Pathologists. Endocr Pathol 35: 167-184.","journal-title":"Endocr Pathol"},{"key":"9851_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","volume":"20","author":"I Landa","year":"2024","unstructured":"Landa I, Cabanillas ME (2024) Genomic alterations in thyroid cancer: biological and clinical insights. Nat Rev Endocrinol 20: 93-110.","journal-title":"Nat Rev Endocrinol"},{"key":"9851_CR31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1089\/thy.2019.0116","volume":"30","author":"H Guan","year":"2020","unstructured":"Guan H, Toraldo G, Cerda S et al. (2020) Utilities of RAS Mutations in Preoperative Fine Needle Biopsies for Decision Making for Thyroid Nodule Management: Results from a Single-Center Prospective Cohort. Thyroid 30: 536-547.","journal-title":"Thyroid"},{"key":"9851_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/PAP.0000000000000368","volume":"30","author":"NP Ohori","year":"2023","unstructured":"Ohori NP, Nishino M (2023) Follicular Neoplasm of Thyroid Revisited: Current Differential Diagnosis and the Impact of Molecular Testing. Adv Anat Pathol 30: 11-23.","journal-title":"Adv Anat Pathol"},{"key":"9851_CR33","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/his.14396","volume":"79","author":"M Saliba","year":"2021","unstructured":"Saliba M, Katabi N, Dogan S, Xu B, Ghossein RA (2021) NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility. Histopathology 79: 650-660.","journal-title":"Histopathology"},{"key":"9851_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12022-024-09821-4","volume":"35","author":"BA Alzumaili","year":"2024","unstructured":"Alzumaili BA, Fisch AS, Faquin WC, Nose V, Randolph GW, Sadow PM (2024) Detection of RAS p.Q61R by Immunohistochemistry in Practice: A Clinicopathologic Study of 217 Thyroid Nodules with Molecular Correlates. Endocr Pathol 35: 219-229.","journal-title":"Endocr Pathol"},{"key":"9851_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12022-016-9466-z","volume":"28","author":"A Crescenzi","year":"2017","unstructured":"Crescenzi A, Fulciniti F, Bongiovanni M, Giovanella L, Trimboli P (2017) Detecting N-RAS Q61R Mutated Thyroid Neoplasias by Immunohistochemistry. Endocr Pathol 28: 71-74.","journal-title":"Endocr Pathol"},{"key":"9851_CR36","doi-asserted-by":"publisher","first-page":"E863","DOI":"10.1210\/jc.2010-1921","volume":"96","author":"MM Moura","year":"2011","unstructured":"Moura MM, Cavaco BM, Pinto AE, Leite V (2011) High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 96: E863-868.","journal-title":"J Clin Endocrinol Metab"},{"key":"9851_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s12022-024-09839-8","volume":"35","author":"B Deyette","year":"2024","unstructured":"Deyette B, Lubin DJ, Cheriyan AM et al. (2024) The Potential Utility of RAS Q61R Immunohistochemistry as a Screening Tool in Pre-operative Fine Needle Aspirates of Medullary Thyroid Carcinoma. Endocr Pathol 35: 385-396.","journal-title":"Endocr Pathol"},{"key":"9851_CR38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/path.5005","volume":"244","author":"J Liang","year":"2018","unstructured":"Liang J, Cai W, Feng D et al. (2018) Genetic landscape of papillary thyroid carcinoma in the Chinese population. J Pathol 244: 215-226.","journal-title":"J Pathol"},{"key":"9851_CR39","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12022-020-09648-9","volume":"31","author":"YC Lee","year":"2020","unstructured":"Lee YC, Chen JY, Huang CJ, Chen HS, Yang AH, Hang JF (2020) Detection of NTRK1\/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing. Endocr Pathol 31: 348-358.","journal-title":"Endocr Pathol"},{"key":"9851_CR40","doi-asserted-by":"publisher","first-page":"100222","DOI":"10.1016\/j.modpat.2023.100222","volume":"36","author":"JF Hang","year":"2023","unstructured":"Hang JF, Lee YC (2023) How Sensitive is Pan-TRK Immunohistochemistry for Detecting NTRK Fusions in Papillary Thyroid Carcinoma? Mod Pathol 36: 100222.","journal-title":"Mod Pathol"},{"key":"9851_CR41","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.5858\/arpa.2020-0400-RA","volume":"145","author":"E Conde","year":"2021","unstructured":"Conde E, Hernandez S, Sanchez E et al. (2021) Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer. Arch Pathol Lab Med 145: 1031-1040.","journal-title":"Arch Pathol Lab Med"},{"key":"9851_CR42","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1038\/s41379-020-0638-5","volume":"33","author":"YH Chu","year":"2020","unstructured":"Chu YH, Wirth LJ, Farahani AA et al. (2020) Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. Mod Pathol 33: 2458-2472.","journal-title":"Mod Pathol"},{"key":"9851_CR43","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/PAS.0000000000000368","volume":"39","author":"A Chou","year":"2015","unstructured":"Chou A, Fraser S, Toon CW et al. (2015) A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol 39: 652-659.","journal-title":"Am J Surg Pathol"},{"key":"9851_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s12022-024-09808-1","volume":"35","author":"KP Shih","year":"2024","unstructured":"Shih KP, Lee YC, Tsai JJ et al. (2024) Clinicopathologic Features and Cytologic Correlation of ALK-Rearranged Papillary Thyroid Carcinoma: A Series of Eight Cases. Endocr Pathol 35: 134-146.","journal-title":"Endocr Pathol"},{"key":"9851_CR45","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1089\/thy.2020.0086","volume":"30","author":"B Xu","year":"2020","unstructured":"Xu B, Fuchs T, Dogan S et al. (2020) Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid 30: 1505-1517.","journal-title":"Thyroid"},{"key":"9851_CR46","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3390\/cancers12071973","volume":"12","author":"WA Lai","year":"2020","unstructured":"Lai WA, Liu CY, Lin SY, Chen CC, Hang JF (2020) Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies RAS and PIK3CA Mutations as Negative Survival Predictors. Cancers (Basel) 12: 1973.","journal-title":"Cancers (Basel)"},{"key":"9851_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12022-024-09836-x","volume":"35","author":"O Mete","year":"2024","unstructured":"Mete O, Boucher A, Schrader KA et al. (2024) Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management. Endocr Pathol 35: 293-308.","journal-title":"Endocr Pathol"},{"key":"9851_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA et al. (2018) Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol 36: 7-13.","journal-title":"J Clin Oncol"},{"key":"9851_CR49","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack SG, Drilon A, Lin JJ et al. (2022) Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 186: 631-643.","journal-title":"Eur J Endocrinol"},{"key":"9851_CR50","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1200\/JCO.2013.49.6596","volume":"33","author":"Y Godbert","year":"2015","unstructured":"Godbert Y, Henriques de Figueiredo B, Bonichon F et al. (2015) Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma. J Clin Oncol 33: e84-87.","journal-title":"J Clin Oncol"},{"key":"9851_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12022-020-09661-y","volume":"32","author":"JM Cameselle-Teijeiro","year":"2021","unstructured":"Cameselle-Teijeiro JM, Mete O, Asa SL, LiVolsi V (2021) Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates. Endocr Pathol 32: 77-101.","journal-title":"Endocr Pathol"},{"key":"9851_CR52","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/ajcp\/aqad177","volume":"161","author":"E Hartsough","year":"2024","unstructured":"Hartsough E, DeSimone MS, Lorenzo ME, Dias-Santagata D, Nose V, Hoang MP (2024) Utilizing PTEN immunohistochemistry as a screening test for Cowden syndrome. Am J Clin Pathol 161: 490-500.","journal-title":"Am J Clin Pathol"},{"key":"9851_CR53","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1097\/PAS.0b013e31822fbc7d","volume":"35","author":"JA Barletta","year":"2011","unstructured":"Barletta JA, Bellizzi AM, Hornick JL (2011) Immunohistochemical staining of thyroidectomy specimens for PTEN can aid in the identification of patients with Cowden syndrome. Am J Surg Pathol 35: 1505-1511.","journal-title":"Am J Surg Pathol"},{"key":"9851_CR54","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1053\/j.semdp.2017.05.004","volume":"35","author":"J Andrici","year":"2018","unstructured":"Andrici J, Gill AJ, Hornick JL (2018) Next generation immunohistochemistry: Emerging substitutes to genetic testing? Semin Diagn Pathol 35: 161-169.","journal-title":"Semin Diagn Pathol"},{"key":"9851_CR55","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41379-018-0070-2","volume":"31","author":"JM Cameselle-Teijeiro","year":"2018","unstructured":"Cameselle-Teijeiro JM, Peteiro-Gonzalez D, Caneiro-Gomez J et al. (2018) Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT\/beta-catenin pathway. Mod Pathol 31: 1168-1179.","journal-title":"Mod Pathol"},{"key":"9851_CR56","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12022-021-09683-0","volume":"32","author":"B Boyraz","year":"2021","unstructured":"Boyraz B, Sadow PM, Asa SL, Dias-Santagata D, Nose V, Mete O (2021) Cribriform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis. Endocr Pathol 32: 327-335.","journal-title":"Endocr Pathol"},{"key":"9851_CR57","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/modpathol.2016.173","volume":"30","author":"C Rebecchini","year":"2017","unstructured":"Rebecchini C, Nobile A, Piana S et al. (2017) Papillary thyroid carcinoma with nodular fasciitis-like stroma and beta-catenin mutations should be renamed papillary thyroid carcinoma with desmoid-type fibromatosis. Mod Pathol 30: 236-245.","journal-title":"Mod Pathol"},{"key":"9851_CR58","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/s41379-020-0539-7","volume":"33","author":"D Suster","year":"2020","unstructured":"Suster D, Michal M, Nishino M et al. (2020) Papillary thyroid carcinoma with prominent myofibroblastic stromal component: clinicopathologic, immunohistochemical and next-generation sequencing study of seven cases. Mod Pathol 33: 1702-1711.","journal-title":"Mod Pathol"},{"key":"9851_CR59","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1507\/endocrj.EJ17-0242","volume":"64","author":"N Takada","year":"2017","unstructured":"Takada N, Hirokawa M, Ito M et al. (2017) Papillary thyroid carcinoma with desmoid-type fibromatosis: A clinical, pathological, and immunohistochemical study of 14 cases. Endocr J 64: 1017-1023.","journal-title":"Endocr J"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09851-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-025-09851-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09851-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:03:42Z","timestamp":1767863022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-025-09851-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9851"],"URL":"https:\/\/doi.org\/10.1007\/s12022-025-09851-6","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"6 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Jen-Fan Hang is an editorial board member of Endocrine Pathology. Dr. Jonathan P. Rivera has no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"8"}}